Keyphrases
C-Myc
100%
High-risk Human Papillomavirus (HR-HPV)
100%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
100%
Cisplatin
100%
Palbociclib
100%
Cyclin-dependent Kinase 4 (CDK4)
100%
Carcinoma Cell Lines
28%
Squamous Carcinoma Cells
28%
Highly Effective
14%
Cell Tumor
14%
Phase I Clinical Trial
14%
Patient Response
14%
Combination Treatment
14%
Cyclin E
14%
Chemo-naive
14%
Tumor Xenograft
14%
Intrinsic Resistance
14%
Cyclin-dependent Kinase 6 (CDK6)
14%
Resistance Mechanisms
14%
Resistance Phenotypes
14%
Response Data
14%
DNA Damage Tolerance
14%
Inhibitor Resistance
14%
Cyclin-dependent Kinase 4/6 Inhibitors
14%
Inherent Resistance
14%
Cisplatin-resistant Cells
14%
Antigrowth
14%
Bromodomain Inhibitors
14%
Growth Effect
14%
Pharmacology, Toxicology and Pharmaceutical Science
Cisplatin
100%
Human Papillomavirus
100%
Head and Neck Squamous Cell Carcinoma
100%
Palbociclib
100%
Cyclin Dependent Kinase 4
28%
Neoplasm
14%
Clinical Trial
14%
Cyclin E
14%
Intrinsic Resistance
14%
Bromodomain Inhibitor
14%
Biochemistry, Genetics and Molecular Biology
Oncogene C Myc
100%
Cisplatin
100%
Wart Virus
100%
Cyclin-Dependent Kinase 4
28%
DNA Damage
14%
Clinical Trial
14%
P16
14%
Cyclin E
14%
Bromodomain
14%